MY106737A - Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4. - Google Patents

Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4.

Info

Publication number
MY106737A
MY106737A MYPI90001264A MYPI19901264A MY106737A MY 106737 A MY106737 A MY 106737A MY PI90001264 A MYPI90001264 A MY PI90001264A MY PI19901264 A MYPI19901264 A MY PI19901264A MY 106737 A MY106737 A MY 106737A
Authority
MY
Malaysia
Prior art keywords
interleukin
neutrophils
methods
myeloid cells
purifying
Prior art date
Application number
MYPI90001264A
Inventor
Raman Jay
L Nagabhushan T
Bonnem Eric
Sullivan Lee
Bober Loretta
Chu-Tay Tang John
Naveh David
Grace Michael
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/531,270 external-priority patent/US5077388A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of MY106737A publication Critical patent/MY106737A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

METHODS FOR INCREASING THE NUMBERS OF NEUTROPHILS AND FOR INDUCING THE MATURATION OF MYELOID CELLS IN MAMMALS BY ADMINISTERING IL-4 ARE DISCLOSED. ALSO DISCLOSED ARE PROCESSES FOR PURIFYING ACTIVE RECOMBINANT HUMAN INTERLEUKIN-4 FROM CERTAIN E. COLI FERMENTATION BROTHS OR FROM CERTAIN CHO-CELL CELL CULTURE MEDIUMS.
MYPI90001264A 1989-07-28 1990-07-26 Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4. MY106737A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38693789A 1989-07-28 1989-07-28
US07/531,270 US5077388A (en) 1990-05-31 1990-05-31 Purification of human interleukin-4 from a secreted escherichia coli mutant

Publications (1)

Publication Number Publication Date
MY106737A true MY106737A (en) 1995-07-31

Family

ID=27011670

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI90001264A MY106737A (en) 1989-07-28 1990-07-26 Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4.

Country Status (3)

Country Link
IE (2) IE75354B1 (en)
MY (1) MY106737A (en)
NZ (1) NZ234665A (en)

Also Published As

Publication number Publication date
IE68840B1 (en) 1996-07-10
IE75354B1 (en) 1997-08-27
IE902718A1 (en) 1991-02-27
NZ234665A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
IL157644A0 (en) Method for the purification of a protein preparation with erythropoietin activity
EP0215126A4 (en) Human granulocyte colony stimulating factor.
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
GR3035627T3 (en) A mammalian cytokine, il-11.
PT85285A (en) Process for producing il-6 and of pharmaceutical compositions containing the same
WO1991001744A3 (en) Uses of interleukin-4 and method for purifying it
ES8801578A1 (en) Polyene antibiotic emulsion formulation.
AU690336B2 (en) Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle
EP0238655A4 (en) Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells.
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
GB8909836D0 (en) Therapeutic agent
ZA887773B (en) Interleukin-7
EP0437610A4 (en) Novel physiologically active polypeptide, recombinant plasmid, recombinant microbial cells, medicinal composition, and process for recovering purified polypeptide
ES8403157A1 (en) A method of manufacturing biological active substance.
AU7685087A (en) Amylolytic enzymes producing microorganisms, constructed by recombinant DNA technology and their use for fermentation processes
AU5218998A (en) Reactive oxygen intermediates containing compounds effective in inducing cell differentiation of malignant cells such as leukemia
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
CA2363269A1 (en) Dna vaccination for treatment of autoimmune disease
MY106737A (en) Methods for increasing numbers of neutrophils, for inducing maturation of myeloid cells with interleukin-4 and purifying interleukin-4.
AU1909995A (en) Co-administration of interleukin-3 mutant polypeptides with csf's for multi-lineage hematopoietic cell production
SE8605459L (en) NEW CELL GROWTH CONTROL FACTOR
JPS6427492A (en) Purification of granulocyte-macrophage colony stimulus factor
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
ES2020176B3 (en) SIZE COMPOSITION OF POLYVINYL ALCOHOL OF HIGH ACTIVITY IN TISSUES, LITTLE FOAMY.
NZ182645A (en) Continuously killing microorganisms in continuous culture of bacteria or yeast to produce single cell protein